Nektar Q3 2020 Earnings Report
Key Takeaways
Nektar Therapeutics reported revenue of $30.0 million and a net loss of $108.6 million for the third quarter of 2020. The company's cash and investments in marketable securities were approximately $1.2 billion as of September 30, 2020.
Advanced late-stage registrational and early stage studies for immune-oncology pipeline.
Enrollment is going well in five registrational bempegaldesleukin trials in combination with nivolumab.
Bristol-Myers Squibb initiated a new clinical study in renal cell carcinoma.
Ahead of enrollment targets for Phase 2 PROPEL study of bempegaldesleukin with pembrolizumab in patients with metastatic non-small cell lung cancer.
Nektar
Nektar
Forward Guidance
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, today, Thursday, November 5, 2020.